|Bid||105.30 x 800|
|Ask||108.99 x 1300|
|Day's range||108.61 - 110.96|
|52-week range||61.28 - 113.60|
|Beta (5Y monthly)||1.26|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Strong demand for Sarepta's (SRPT) DMD drugs boosts the top line in the second quarter. However, the wider-than-anticipated losses drive the stock down in after-market trading.
Good day, ladies and gentlemen, thank you for standing by, and welcome to Sarepta Therapeutics second quarter 2022 earnings conference call. Actual results could materially differ from these forward-looking statements, and any such risks can materially and adversely affect the business, the results of operations, and trading prices for Sarepta's common stock.
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -147.66% and 6.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?